Lupus erythematosus (LE) is a multifactorial autoimmune disease with clinical manifestations of differing severity which may present with skin manifestations as primary sign of the disease (cutaneous lupus erythematosus, CLE) or as part of a disease spectrum (systemic lupus erythematosus, SLE). To date, no drugs are approved specifically for the treatment of CLE and only single agents have been applied in randomized controlled trials. Therefore, topical and systemic agents are used ''off-label'', primarily based on open-label studies, case series, retrospective analyses, and expert opinions. In contrast, several agents, such as hydroxychloroquine, chloroquine, cyclophosphamide, azathioprine, and belimumab, are approved for the treatment of SLE. Recent approaches in the understanding of the molecular pathogenesis of LE enabled the development of further new agents, which target molecules such as interleukin 6 (IL-6) and interferon (IFN). Only single trials, however, applied these new agents in patients with cutaneous involvement of the disease and/or included endpoints which evaluated the efficacy of these agents on skin manifestations. This article provides an updated review on new and recent approaches in the treatment of CLE. Lupus (2016) 25, 830-837.
Introduction
The inflammatory autoimmune disease lupus erythematosus (LE) is characterized by a broad spectrum of clinical manifestations and may affect many different tissues and organs, such as the skin, heart, lung and kidney. Cutaneous manifestations may occur as primary sign of the disease (cutaneous lupus erythematosus, CLE) or as part of a disease spectrum (systemic lupus erythematosus, SLE). 1 The broad variety of LE-specific skin lesions in this disease has led to the practice of identifying four subtypes: (i) acute cutaneous LE (ACLE), (ii) subacute cutaneous LE (SCLE), (iii) chronic cutaneous LE (CCLE), which consists of discoid LE (DLE), LE panniculitis (LEP) and chilblain LE (CHLE), and (iv) intermittent cutaneous LE (ICLE), including LE tumidus (LET). 2 To date, no drugs are approved specifically for the treatment of CLE and only single agents have been used in randomized controlled trials. 3, 4 Therefore, topical and systemic agents are applied ''off-label'', primarily based on open-label studies, case series, retrospective analyses, and expert opinions. In contrast, several agents, such as hydroxychloroquine, chloroquine, cyclophosphamide, and azathioprine are approved for the treatment of SLE. Recently, the human monoclonal antibody belimumab, a B lymphocyte stimulator (BlyS) inhibitor, has been the first drug after 50 years licensed for this autoimmune disease as an adjunct therapy for autoantibody-positive patients who despite standard therapy show high disease activity, intolerance of other treatments, or have an unacceptably high need for corticosteroids. 5 Recent approaches in the understanding of the molecular pathogenesis of LE enabled the development of further new agents, which target molecules such as interleukin-6 (IL-6) and interferon (IFN). Only single trials, however, applied these new agents in patients with cutaneous involvement of the disease and/or included endpoints which evaluated the efficacy of these agents on skin manifestations. The aim of this article is to provide an updated review on new and recent approaches in the treatment of CLE based on a selective survey of the published literature and on entries of trials which apply novel therapeutic strategies included at https://www.clinicaltrials.gov.
Interleukin 6
In patients with SLE, abnormal biological activities of cytokines have been observed and several studies suggest an association of proinflammatory cytokines, such as interleukin 6 (IL-6), with disease activity and specific clinical manifestations. 6 IL-6 is a pleiotropic cytokine, which is responsible for a broad variety of biologic activities. For example, increased levels of IL-6 induce the differentiation of B cells into antibody-forming cells, 7 resulting in an increased production of autoantibodies, such as anti-double-stranded DNA (anti-dsDNA) antibodies, immune complex deposition, and inflammation in various tissues and organs. 8 Moreover, IL-6 stimulates the maturation of B cells, the secretion of immunoglobulins, and the production and differentiation of cytotoxic T cells. 9 In 2007, Chun et al. 10 evaluated the levels of IL-6 in the sera of 166 patients with SLE and 40 healthy controls and correlated the results with the disease activity of the included patients as measured with the Safety of Estrogens in Lupus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI). In patients with SLE, IL-6 was observed to be significantly higher compared to healthy controls; moreover, in patients with ''hyperactive'' SLE (SELENA-SLEDAI 12) significantly higher levels of IL-6 were observed compared to patients with ''active'' (SELENA-SLEDAI of 6-11) or ''inactive'' (SELENA-SLEDAI of <6) SLE. Therefore, it has been suggested that therapeutic options for refractory SLE might include antibodies targeting IL-6 and the IL-6 receptor. 11, 12 Sirukumab, a fully humanized anti-IL-6 monoclonal antibody, binds to IL-6 with high affinity and specificity. A randomized, double-blind, placebo-controlled, open-labelled, dose-ascending phase I study evaluated the safety and pharmacokinetics of multiple intravenous infusions of sirukumab in 31 patients with CLE and 15 patients with SLE. 13 However, the concentration of IL-6 in the sera of patients who received sirukumab increased after treatment. This apparent paradox may have been caused by the binding of sirukumab to soluble IL-6 leading to the formation of immune complexes, which were then identified by the IL-6 enzyme immunoassay. In this study, it has further been observed that levels of C-reactive protein (CRP), a commonly used surrogate marker for IL-6, were suppressed after treatment with sirukumab. These results suggest that even though the concentration of IL-6 (including the immune-complexed form) was increased, the corresponding inflammatory pathway was suppressed. As evaluated by the CLE Disease Area and Severity Index (CLASI), no significant changes compared to baseline were observed in patients with CLE (decrease from 6 points to 3 points) and in patients with SLE (decrease from 4 points to 1.5 points) who received sirukumab. Moreover, in patients with CLE and SLE who received placebo, a similar response was observed (decrease from 10.5 points to 7 points and from 2 points to 1 point, respectively). Nevertheless, SLE patients receiving sirukumab showed a slight improvement in the musculoskeletal domain of the British Isles Lupus Assessment Group (BILAG) in week eight compared to patients receiving placebo, but no clear differences were observed between the sirukumab group and the placebo group over time. 13 Therefore, further trials are warranted to define conclusions on the efficacy of sirukumab in CLE and SLE patients.
Tocilizumab is a humanized monoclonal antibody, which neutralizes the pleiotropic actions of IL-6 by preventing the binding of these molecules to membrane-bound and soluble IL-6 receptors. 14 In a phase I, dose-escalation study, this agent was administered to 16 SLE patients with mild-to-moderate disease activity. 12 The observed clinical and serological results of this study, such as the decrease of inflammation markers and improvement in haemoglobin and serum albumin levels, suggest that tocilizumab effectively blocks IL-6 in patients with SLE. However, no trials on the efficacy of this agent for the treatment of patients with CLE have yet been performed, only one case report described the successful application of tocilizumab in a 22-year-old female patient with refractory SLE, skin lesions of LET and urticarial vasculitis. 14 The patient showed a favourable response with remission of fever, arthritis and skin manifestations. Further data on the efficacy of tocilizumab are warranted to evaluate the efficacy of this agent in CLE.
Interferon
A strong activation of type I IFN-driven pathways is a hallmark of the molecular mechanisms in LE, as several IFN-regulated cytokines are highly up-regulated in CLE and SLE. 15 This ''IFN-signature'' was first identified in gene expression of peripheral blood cells in patients with SLE, where it was associated with an increased disease activity. 16, 17 In CLE, IFNmediated proinflammatory mechanisms also play an important functional role. MxA, a specific marker for type I/III IFN production, is strongly expressed within the epidermis of active skin lesions. 18 Importantly, the expression of CXCL10 in the skin, a further IFN-regulated cytokine, determines the inflammatory pattern of CLE. This cytokine, which is specifically expressed in the lower epidermis of inflamed skin, drives the recruitment of CXCR3þ effector cells (mainly T cells and plasmacytoid dendritic cells, pDCs) and orchestrates the CLE-typical ''interface dermatitis''. 19, 20 Importantly, large numbers of ''natural IFN-producing'' pDCs are a typical feature of skin lesions in CLE. These pDCs form clusters of more than 20 cells, a histological hallmark which can be used to distinguish specific CLE subtypes (particularly LET) from other inflammatory skin disorders. 21 Moreover, non-immune cells appear to contribute to the lesional IFN production, such as keratinocytes, which are able to produce large amounts of type III IFN upon adequate stimulation. 22 Three recent gene-expression analyses support the role of IFNs in CLE: Dey-Rao et al. 23, 24 evaluated genome-wide gene expression data and compared lesional and non-lesional skin from patients with DLE. The authors identified a set of 513 genes, which were up-regulated in lesional skin; 117 of the up-regulated genes were associated with apoptosis and 131 were associated with type I IFN signalling, supporting the role of these pathways in the pathogenesis of CLE. Jabbari et al. 25 compared the transcriptome in lesional skin of DLE patients with the transcriptomes in lesional skin of patients with psoriasis and the skin of healthy controls. In the skin of DLE patients, a predominance of cells and of IFN-regulated genes was observed. Recently, our group made similar observations in the skin of DLE and SCLE patients: Both CLE subtypes presented with a high expression of IFNregulated genes and a strong activation of innate immune system pathways. 26 As stated above, skin lesions of CLE patients are characterized by a strong expression of IFN-regulated proinflammatory cytokines. [24] [25] [26] These IFNs are part of the innate immune system and are supposed to drive the lesional inflammation by stimulating adaptive cytotoxic immune responses, which mediate cell death and apoptosis in CLE. 15 Recent studies indicate that immunostimulatory nucleic acids, which are released due to the death of the cytotoxic cells, and DNA-containing neutrophil extracellular traps 27 are potent stimulators on the innate immune system, may stimulate the lesional IFN production and fuel the proinflammatory vicious circle in LE. 1 Consequently, the type I IFN system has become a potential therapeutic target in this autoimmune disease.
Sifalimumab (a human anti-IFN-alpha monoclonal antibody) was the first anti-IFN antibody tested in patients with SLE. This antibody induced a significant reduction of the type I IFN gene signature in patients with a high baseline signature, but caused no statistically significant difference in disease activity. 28 In a recent phase IIb, randomized, double-blind, four-arm, placebo-controlled study, the efficacy and safety of 200 mg, 600 mg or 1200 mg sifalimumab was evaluated in 431 patients with SLE. 29 After 365 days of treatment, disease activity was significantly reduced in the group of patients receiving sifalimumab compared to patients receiving placebo. In patients who presented with moderate to severe mucocutaneous involvement at baseline, treatment with 200 mg and 1200 mg sifalimumab resulted in a significant improvement compared to patients treated with placebo.
Recently, a phase II, randomized, double-blind, placebo-controlled multicenter trial evaluated the efficacy and safety of rontalizumab, a humanized immunoglobulin G1 anti-IFN-alpha monoclonal antibody, in 238 patients with SLE. 30 The response rates were similar between the rontalizumab and placebo group and the study did not meet its primary efficacy endpoint, which might have been due to the specificity of the applied antibodies and the large number of different type I IFNs. 31 However, an exploratory analysis of the data suggests an improvement of disease activity, reduced flares, and a reduction of steroid use in a subgroup of SLE patients with a low IFN signature metric score.
As all these IFNs bind to one common IFN receptor, anifrolumab, a therapeutic anti-interferon-a/-b/-o-receptor was developed. This drug suppresses the IFN signature in the blood and skin, demonstrated in a phase I trial including patients with systemic sclerosis, an autoimmune disease closely related to SLE. 32 Recently, published data of a randomized, double-blind, placebo-controlled phase II trial showed significant improvement of disease activity in a cohort of 305 patients with SLE. 33 Importantly, anifrolumab was reported to reduce skin rashes, suggesting a potential efficacy of this agent also in CLE. 33 
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Kinase inhibitors
As detailed above, skin lesions of CLE patients are characterized by a strong activation of several immune response pathways. These include pathways of the innate (toll-like receptor (TLR)-dependent/independent, nuclear factor-kB (Nf-kB), apoptosis, mitogen-activated protein (MAP)-kinase, janus kinase (JAK)/signal transducer and activator of transcription (STAT)) as well as of the adaptive (e.g. antigen processing and presentation, leukocyte transendothelial migration, B-cell receptor signalling pathway, or T-cell receptor signalling pathway) immune system. [24] [25] [26] Recent advances in the development of small molecules specifically inhibiting these pathways, i.e. kinase inhibitors, opened the door for a new therapeutic intervention. Kinase inhibitors were primarily developed for the treatment of neoplastic diseases, but an additional immunosuppressive effect was observed in clinical practice. 34 These findings particularly apply to ruxolitinib, a JAK1/2-inhibitor, originally developed for the treatment of JAK2-mutated myeloproliferative disorders. This drug has been approved by the US Food and Drug Administration (FDA) for the treatment of intermediate or high-risk myelofibrosis but also has a significant immunosuppressive effect. It first became evident in clinical trials, where the application of ruxolitinib was associated with an increased rate of opportunistic infections. 35 By blocking the JAK/STAT pathway, ruxolitinib inhibits the activation of NK cells, blocks the downstream signaling of the IFN-alpha/beta receptor and inhibits the expression of several proinflammatory cytokines. 36, 37 Importantly, these JAK/ STAT regulated cytokines include several IFNregulated proinflammatory factors (CXCL-9, -10 and -11), making JAK/STAT-inhibitors interesting candidates for new therapeutic agents in CLE. This hypothesis is supported by clinical data: In graft versus host disease, a reactive immunological disorder which histologically is characterized by an interface dermatitis similar to CLE, ruxolitinib has been demonstrated to drive regulatory T-cell (Treg) expansion and to inhibit the development of skin lesions. 38 Recently, our group published a case of severe dermatomyositis, an autoimmune disease also closely connected to CLE, which responded well to ruxolitinib. 39, 40 The drug also has been shown to be effective in other immunological skin disorders, including psoriasis and alopecia areata, underlining its anti-inflammatory properties. 41, 42 Ruxolitinib was also observed to attenuate lupus-like skin lesions in MRL/lpr mice. 43 These pre-clinical findings are supported by observations of our group in a 69-year-old patient with CHLE, whose skin lesions responded very well to the treatment with ruxolitinib. 44 In accordance with these findings, other JAKpathway inhibitors were also observed to be effective in inflammatory disorders of the skin and might provide future therapeutic alternatives for patients with CLE: The JAK1/3 inhibitor tofacitinib citrate was found to be effective in the treatment of recalcitrant atopic dermatitis 45 as well as in vitiligo. 46 Moreover, the JAK 1/2 inhibitor barictinib was highly effective in a case of recalcitrant alopecia areata. 47 Importantly, all these JAK/STAT pathways inhibitors are no ''magic bullets'' but immunosuppressive drugs. Therefore, the high efficacy in inflammatory diseases can be accompanied by an increased infection rate. 48, 49 In addition to JAK/STAT, several other proinflammatory pathways are involved in the pathogenesis of CLE and might provide potential future therapeutic targets. These pathways include the MAP-kinases pathway, which provides potential targets in the disease. Inappropriate activation of MAP-kinases has been linked to several autoimmune diseases including SLE, rheumatoid arthritis and inflammatory bowel disease. 50, 51 FR167653 is a potent inhibitor p38-MAP-kinase inhibitor, which was observed to reduce lupus-like disease activity in MRL/lpr mice. 52 These data are supported by data of another selective p38-MAPKinhibitor (SB203580), which prolongs survival and reduces lupus nephritis in MRL/lpr mice. 53 In human peripheral blood cells isolated from patients with SLE, SB203580 reduced the production of proinflammatory cytokines. 54 Spleen tyrosine kinase (Syk), a non-receptor tyrosine kinase, has also been associated with active LE. After phosphorylation, this kinase activates downstream pathways (including NF-kB), which mediate cellular cytotoxicity and cytokine production. 55 In SLE, Syk has been suggested to drive the elevated T-cell activation, 56 but it is probably also involved in the pathogenesis of CLE, as skin lesions of this disease are characterized by an increased expression of phosphorylated Syk. 26 Fostamatinib (R788) is a Syk-inhibitor, which reduces disease activity in murine lupus models (NZB/W-and MRL/lpr-mice) but also improves lupus-like skin lesions (MRL/lpr-mice). 57, 58 A potential role for Syk inhibition is supported by recent data of our group showing that GSK143, another Syk-inhibitor, significantly reduces the expression of lupus-like chemokines in an in vitro epidermal skin model. 26 In summary, anti-inflammatory kinase-inhibitors provide a very promising class of new drugs for the treatment of CLE. The fact that most of these drugs are small molecules which penetrate easily into the skin makes these agents very attractive for topical use in inflammatory skin disorders. 59, 60 
Drugs targeting B-cells
BLyS is a member of the tumor necrosis factor (TNF) ligand superfamily and contributes to B-cell proliferation and differentiation. In addition to high serum levels of BLyS in SLE patients, 61 increased serum levels of BLyS are also seen in patients with alopecia areata 62 and psoriasis. 63 It has further been shown that T cells infiltrating labial salivary glands from patients with Sjo¨gren's syndrome express BLyS. 64 Moreover, T cells positive for the BLyS receptor TACI were detected in synovial tissue samples from patients with rheumatoid arthritis and synovitis. 65 These data confirm that BLyS plays an important role in B-and T-cell-mediated diseases.
Belimumab is a human monoclonal antibody, which blocks the binding of soluble BLyS to receptors on B cells. 66 Although belimumab does not directly bind to B cells, it inhibits the survival of B cells, including autoreactive B cells, and also reduces the differentiation of B cells into immunoglobulin-producing plasma cells. Therefore, belimumab is the first of a new class of immunomodulators with a novel mechanism of action, which was approved in 2011 based on two phase III studies (BLISS-52 and BLISS-76) as add-on therapy in patients with autoantibody-positive SLE with high disease activity unresponsive to other treatments and or an unacceptably high need for corticosteroids. 67, 68 One year later, a post hoc analysis was performed in the 1684 autoantibody-positive SLE patients included in the phase III trials and SLE disease activity was assessed by the SELENA-SLEDAI and the BILAG. 5 The data demonstrated that belimumab plus standard SLE therapy showed a significantly higher efficacy than placebo plus standard therapy. In addition, a reduced disease activity on musculoskeletal and mucocutaneous parameters was observed in the applied scores. 5 However, the mucocutaneous manifestations in SLE patients were not further specified and a validated skin activity and damage score, e.g. the ''Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index'' (RCLASI), 69 was not applied in these phase III trials. Therefore, it is difficult to evaluate and reproduce the efficacy of belimumab on mucocutaneous lesions in SLE patients, and future prospective studies using a validated skin score are required. Currently, an analysis is ongoing to investigate if BLyS and/or its receptors are expressed in skin biopsies of patients with different subtypes of CLE. The results of this analysis will be of high interest to support the hypothesis that belimumab is an efficient therapeutic agent for skin lesions of the disease.
Other approaches: Phosphodiesterase (PDE) inhibitors and treatment with regulatory T cells (Treg)
Phosphodiesterases (PDE) are enzymes that metabolize cyclic adenosine monophosphate (cAMP), a second messenger for a variety of hormones, inflammatory mediators and cytokines. 70, 71 PDE type 4 (PDE4) is expressed in cells that play a major role in the pathogenesis of inflammatory diseases, such as T cells, B cells, and dendritic cells. 72 Therefore, PDE4 inhibitors are evaluated for the treatment of inflammatory and immune mediated diseases, such as CLE. A recently conducted phase I/II study aimed to determine the clinical and immunological effects of the PDE4 inhibitor, CC-10004, in patients with CLE (ClinicalTrials.gov Identifier: NCT00708916). The results of this study have not yet been published. Natural CD4þCD25þ Treg are mediators of peripheral tolerance and potent suppressors of immune responses induced by auto-reactive T cells. 73, 74 Several studies reported a deficiency of Treg and/or of their function in human autoimmune diseases, such as type 1-diabetes 75 or multiple sclerosis. 76 In SLE, conflicting data on the role of CD4þCD25þ Treg have been published. 77 Most studies on SLE reported decreased numbers of Treg in the peripheral blood, 78,79 but normal or even increased numbers of CD4þCD25þ Treg have also been described. 80 In addition, both deficient 81 and non-impaired 73, 82 suppressive capacity of isolated Treg were reported in SLE. The results of a currently ongoing phase I study evaluating the safety and tolerability of treatment with ex vivo autologous CD4þCD127lo/-CD25þ polyclonal Treg in patients with SLE and skin lesions (ClinicalTrials.gov Identifier: NCT02428309) will be of high interest to evaluate the impact of aberrant 
Summary
Due to growing insights into the pathogenesis of CLE at the cellular and molecular levels, novel targeted treatment options are becoming available or under development. The analysis of diagnostic biomarkers may be helpful to classify the patients into subgroups, which differ in their response to specific therapeutic strategies. According to the new approach of ''precision medicine'', disease treatment and prevention takes into account individual variability in genes, environment and lifestyle. This approach could prevent harmful drug reactions and increase the efficacy of the applied agents significantly. For example, biomarkers, such as IL-6 or phosphorylated Syk, may be used as diagnostic approach and targeted therapy for patients with CLE in the future. New treatment modalities in SLE patients should also focus on the improvement of skin lesions and apply a validated skin score, such as the RCLASI. To date, only single randomized controlled trials applied new agents in patients with CLE or SLE and skin involvement. Therefore, further prospective trials are warranted to evaluate the efficacy of new therapeutic strategies in skin manifestations of this autoimmune disease and to define the specific role of biomarkers in the different CLE subtypes. Only studies are listed, in which a skin score is applied to evaluate skin manifestations. CLE, cutaneous lupus erythematosus. SLE, systemic lupus erythematosus. TNF, tumor necrosis factor. IL-6, interleukin-6.
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